TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04551105

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group X - Session 1
Description: Each rater in Reader Group X will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group Y - Session 1
Description: Each rater in Reader Group Y will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group X - Session 2
Description: Each rater in Reader Group X will interpret the dataset A cases in different random order with BR-USCAD DS and interpret the dataset B cases in different random order without BR-USCAD DS.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Reader Group Y - Session 2
Description: Each rater in Reader Group Y will interpret the dataset A cases in different random order without BR-USCAD DS and interpret the dataset B cases in different random order with BR-USCAD DS.
Study: NCT02939105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ CoolSculpting System
Description: The CoolSculpting device will be used to perform treatments.
Study: NCT03105050

Intervention type: OTHER
Intervention: Access to bariatric surgery
Description: All countries representatives will be interviewed on their Healthcare systems
Study: NCT03128749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams \& Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
Study: NCT02528292

Intervention type: PROCEDURE
Intervention: Synovial biopsy
Description: Ultrasound guided synovial biopsy of inflamed joint

Intervention type: DRUG
Intervention: Anti-TNF therapy
Description: Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
Study: NCT01383941

Intervention type: DRUG
Intervention: Guidelines-based asthma and rhinitis/rhinosinusitis therapy
Description: All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
Study: NCT02563041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% TSC
Description: The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
Study: NCT01117311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNB on
Description: The implanted Vagal Nerve Blocker will be on at the time of study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNB on
Description: The implanted Vagal Nerve Blocker will be on at the time of study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNB off
Description: The implanted Vagal Nerve Blocker will be off at the time of study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNB off
Description: The implanted Vagal Nerve Blocker will be off at the time of study.
Study: NCT01812044

Intervention type: DRUG
Group type: OTHER
Intervention: subtenons anesthetic - preservative-free bupivacaine 0.75%

Intervention type: DRUG
Group type: OTHER
Intervention: topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel
Study: NCT02435498

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: The online video will contain the same information within the website.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
Study: NCT03089502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
Study: NCT04042259

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abthera
Description: Negative Pressure Wound Therapy Device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open adbdomen for post-laparotomy without NPWT device
Description: Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
Study: NCT03423914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only Writing
Description: Participants write about knowledge related to infant care during four days
Study: NCT03296267

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastroduodenoscopy
Description: Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
Study: NCT02552329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
Study: NCT04417127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Community-Based (ICB) Care
Description: The intervention will include the following components: (1) integrated care visits by clinical team occurring monthly during months 1-6 of the trial, and then quarterly for the remaining months (7-18), which include vital signs screening, consultation with a clinical officer, medication distribution (ART and other chronic and acute medications), and point- of-care (POC) laboratory testing (creatinine, blood glucose and hemoglobin A1C, and viral load as it becomes available); (2) peer support for promoting ART adherence during every monthly MF meeting; (3) referrals to facilities for emergency or acute care needs that are not feasible to address in the community. Integrated care refers to delivery of primary, HIV and NCD-related care, incorporating a focus on both chronic and acute needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfinance
Description: Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microfinance
Description: Group microfinance uses a client-driven model that involves community savings groups where members mobilize and manage their own savings, provide interest-bearing loans to group members, offer a limited form of financial insurance, and contribute to a social fund that is used for income-generating activities and in cases of emergency or welfare issues of group members.~For this study, group microfinance will refer to existing, active AMPATH Group Integrated Savings for Empowerment (GISE) microfinance groups with a majority of group members who are AMPATH HIV patients and have disclosed their HIV status. Groups will be considered active if the group was formed at least 6 months prior to study baseline, is consistently meeting as scheduled, and is actively engaging in saving and loaning.
Study: NCT01306968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham hyperbaric air
Description: A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
Study: NCT04022759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual with Security Prime
Description: In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (Behavioural Activation)
Description: Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
Study: NCT01441401

Intervention type: DRUG
Intervention: gabapentin
Description: According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
Study: NCT01126359

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Saline
Description: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Saline
Description: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
Study: NCT01277107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaleplon AP formulation
Description: Gastric retentive dual release Zaleplon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Identical placebo capsule
Study: NCT00547209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: air
Description: 60% air combined with 40% oxygen for ventilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: 60% nitrous oxide combined with 40% oxygen for ventilation
Study: NCT02343497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01916759

Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
Description: Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
Study: NCT01812044

Intervention type: DRUG
Group type: OTHER
Intervention: topical control - 0.5 cc of Hypromellose 0.3% gel

Intervention type: DRUG
Group type: OTHER
Intervention: topical control - 0.5 cc of Hypromellose 0.3% gel
Study: NCT01916759

Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
Description: Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.

Intervention type: DRUG
Group type: OTHER
Intervention: Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
Description: Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
Study: NCT04117048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabPad® point-of-care
Description: All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
Study: NCT04503707

Intervention type: DRUG
Intervention: Follitropin Delta
Description: The Intervention (solution for injection) is delivered with a pre-filled injection pen. The REKOVELLE dose will be based on a recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the ELECSYS AMH Plus Immunoassay.
Study: NCT02246231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR imaging
Study: NCT04352621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: Ketamine 0.5 mg/kg will be administered intranasally using an atomization device with a maximum dose of 40 mg followed by 6 weeks of rTMS treatment. .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS treatment
Description: patients will begin the open label trial of rTMS per the FDA-approved method on day 1 (the day after the Baseline Visit).
Study: NCT00742859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betrixaban
Description: orally, once daily for at least 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betrixaban
Description: orally, once daily for at least 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betrixaban
Description: orally, once daily for at least 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin will be prescribed by the investigator according to the standard of care.
Study: NCT02630004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin oral gel 3%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral gel
Study: NCT04171089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child- Safety Plan Intervention
Description: The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
Study: NCT03666299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
Study: NCT01508923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
Study: NCT02996461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA090-00-VP
Description: VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
Study: NCT00993629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnenolone
Description: Administered adjunctively to treatment as usual

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: adjunctive placebo
Study: NCT00003276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01812044

Intervention type: DRUG
Group type: OTHER
Intervention: subtenons control - 0.5 cc of Normal Saline

Intervention type: DRUG
Group type: OTHER
Intervention: subtenons control - 0.5 cc of Normal Saline
Study: NCT02742103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL_112
Description: CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight/volume sodium chloride solution (ie, normal saline)
Study: NCT01297218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Description: DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
Study: NCT03447327

Intervention type: PROCEDURE
Group type: OTHER
Intervention: single burr hole
Description: patients with CSDH operated by single burr hole craniostomy under local anaesthesia
Study: NCT01818336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillin skin test kit
Description: Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
Study: NCT01709318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAC)
Description: Daily release of 500, 700, or 900 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAC)
Description: Daily release of 500, 700, or 900 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAC)
Description: Daily release of 500, 700, or 900 μg.
Study: NCT04435912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 200mg IV
Description: single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine